Loading...
Docoh

Hologic (HOLX)

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment.

Company profile

Ticker
HOLX
Exchange
Website
CEO
Stephen MacMillan
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Acessa Health Inc. • Beijing Hologic Technology Co., Ltd. • Benassar Diagnostica-Equipamientos Medicos Unipessoal, Lda. • BioLucent, LLC • Bioptics, Inc. • Biotheranostics, Inc. • Cytyc Corporation • Cytyc Prenatal Products Corp. • Cytyc Surgical Products, LLC • Diagenode Co., Ltd. ...
IRS number
42902449

HOLX stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

27 Apr 22
2 Jul 22
28 Sep 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Sep 21 Sep 20 Sep 19 Sep 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
17 May 22 Benjamin Jordan Cohn Common Stock Sell Dispose S No No 78.754 3,844 302.73K 13,532
17 May 22 Benjamin Jordan Cohn Common Stock Option exercise Acquire M No No 40.85 3,844 157.03K 17,376
17 May 22 Benjamin Jordan Cohn NQSO Common Stock Option exercise Dispose M No No 40.85 3,844 157.03K 0
17 May 22 Jan Verstreken Common Stock Sell Dispose S No No 78.795 6,500 512.17K 64,191
13 May 22 Benjamin Jordan Cohn Common Stock Sell Dispose S No No 75.49 3,842 290.03K 13,532
13 May 22 Benjamin Jordan Cohn Common Stock Option exercise Acquire M No No 40.85 3,842 156.95K 17,374
13 May 22 Benjamin Jordan Cohn Common Stock Sell Dispose S No No 75.493 3,210 242.33K 13,532
13 May 22 Benjamin Jordan Cohn Common Stock Option exercise Acquire M No No 37.64 3,210 120.82K 16,742
13 May 22 Benjamin Jordan Cohn NQSO Common Stock Option exercise Dispose M No No 40.85 3,842 156.95K 3,844
13 May 22 Benjamin Jordan Cohn NQSO Common Stock Option exercise Dispose M No No 37.64 3,210 120.82K 0

Financial report summary

?
Risks
  • The COVID-19 pandemic and associated economic disruptions have had and may continue to have a material adverse effect on manufacturing, distribution and supply chain.
  • Continuing worldwide political and social uncertainty, as well as tariffs and social tensions, may adversely affect our business and prospects, both domestically and internationally.
  • Our international operations and foreign acquisitions expose us to additional operational challenges that we might not otherwise face.
  • Our reliance on one third-party manufacturer for certain of our product lines and a limited number of suppliers for some key raw materials, components and subassemblies for our products exposes us to increased risks associated with production delays, delivery schedules, manufacturing capability, quality control, quality assurance and costs.
  • Interruptions, delays, shutdowns or damage at our manufacturing or laboratory facilities could harm our business.
  • Our Diagnostics segment depends on a small number of customers for a significant portion of its product sales, and the loss of any of these customers or any cancellation or delay of a large purchase by any of these customers could significantly reduce revenues in our Diagnostics segment.
  • We utilize distributors for a portion of our sales, the loss of which could harm our revenues in the territory serviced by these distributors.
  • Our success depends on our ability to attract, motivate and retain key personnel and plan for future executive transitions.
  • Increased cybersecurity requirements, vulnerabilities, threats and more sophisticated and targeted computer crime could pose a risk to our systems, networks, products, solutions, services and data.
  • Failure to comply with laws relating to the confidentiality of sensitive personal information or standards related to the transmission of electronic health data, may require us to make significant changes to our products, or incur penalties or other liabilities.
  • Healthcare cost containment legislation and the failure of third-party payors to provide appropriate levels of coverage and reimbursement for the use of products and treatments facilitated by our products could harm our business and prospects.
  • Guidelines, recommendations and studies published by various organizations may reduce the use of our products.
  • Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company's operating results.
  • We operate in a highly regulated industry, and changes in healthcare laws and regulations or our inability to obtain in a timely manner or at all U.S. or foreign regulatory clearances or approvals for our current and newly developed products and services or product or service enhancements, could adversely affect our business and prospects.
  • Some of our activities may subject us to risks under federal and state laws prohibiting “kickbacks” and false or fraudulent claims.
  • We are subject to the risk of product liability claims relating to our products for which we may not have adequate insurance.
  • We are subject to environmental, health and safety laws and regulations, including related to our use and recycling of hazardous materials and the composition of our products.
  • Our business is dependent on technologies we license, and if we fail to maintain these licenses or license new technologies and rights to particular nucleic acid sequences for targeted diseases in the future, we may be limited in our ability to develop new products.
  • Our business could be harmed if we are unable to protect our proprietary technology.
  • Our business could be harmed if we infringe upon the intellectual property rights of others.
  • We may not be able to generate sufficient cash flow to service all of our indebtedness and other obligations.
  • A significant portion of our indebtedness is subject to floating interest rates, which may expose us to higher interest payments.
  • The proposed discontinuation or replacement of LIBOR would require us to amend certain agreements and may otherwise adversely affect our business.
  • Provisions in our charter, bylaws, and indebtedness may have the effect of discouraging advantageous offers for our business or common stock and limit the price that investors might be willing to pay in the future for shares of our common stock.
  • Our stock price is volatile.
Management Discussion
  • All dollar amounts in tables are presented in millions.
  • We had a decrease in product revenues in both the current three and six month periods of 8.0% and 9.3%, respectively, compared to the corresponding periods in the prior year. This was primarily due to the decrease in revenues in the Diagnostics business as COVID-19 assay sales were lower, and to a lesser extent, there was also a decrease in Breast Health revenue primarily due to supply chain constraints.
  • Diagnostics product revenues decreased $78.7 million and $262.3 million, or 7.5% and 12.2%, respectively, in the current three and six month periods compared to the corresponding periods in the prior year primarily due to a decrease in Molecular Diagnostics of $74.3 million and $261.6 million, respectively, a decrease in Blood Screening of $2.6 million and $4.7 million, respectively, and a decrease in Cytology & Perinatal for the current three month period of $1.8 million. Cytology & Perinatal revenue increased $4.0 million in the current six month period compared to the corresponding prior year period. Molecular Diagnostics product revenue was $842.9 million and $1,637.7 million, respectively, in the current three and six month periods compared to $917.2 million and $1,899.4 million in the corresponding periods in the prior year. The decrease was primarily attributable to a decrease of $95.1 million and $317.8 million, respectively, in sales from our two SARS-CoV-2 assays due to lower volumes , which we primarily attribute to lower demand from an improvement in the COVID-19 pandemic compared to the prior year and a decrease in average selling prices. We also had a decrease in the sale of our Panther and Panther Fusion instruments in the current year periods compared to the prior year periods. These decreases were partially offset by an increase in sales of $14.6 million and $39.6 million in the current three and six month periods for our Aptima assays and STD collection kits (exclusive of our Aptima SARS-CoV-2 assays), which primarily consisted of our CTGC, Bacterial Vaginosis, and CV Candida assays, on a worldwide basis as volumes increased, partially offset by lower HPV assay volumes. In addition, we had an increase from our Quant Viral assays as well as an increase of $8.7 million and $25.0 million, respectively, in the current three and six month periods from the inclusion of our recent acquisitions of Mobidiag and Diagenode. We also experienced a decrease in revenue from the unfavorable foreign currency exchange impact of the strengthened U.S. dollar against a number of currencies.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: advertising, Bowl, carryback, certified, death, inflow, influenza, milestone, Omicron, parainfluenza, Quant, slowdown, STD, Super, syncytial, Ukraine, unvested, uptick
Removed: added, cancelled, collateral, consulting, divested, division, eased, favorable, GBS, implement, IVDR, MDR, outflow, Pap, recover, significantly, unbenefited, Vitro

Patents

Utility
System and Method for Hierarchical Multi-level Feature Image Synthesis and Representation
23 Jun 22
A method for processing breast tissue image data includes processing the image data to generate a set of image slices collectively depicting the patient's breast; for each image slice, applying one or more filters associated with a plurality of multi-level feature modules, each configured to represent and recognize an assigned characteristic or feature of a high-dimensional object; generating at each multi-level feature module a feature map depicting regions of the image slice having the assigned feature; combining the feature maps generated from the plurality of multi-level feature modules into a combined image object map indicating a probability that the high-dimensional object is present at a particular location of the image slice; and creating a 2D synthesized image identifying one or more high-dimensional objects based at least in part on object maps generated for a plurality of image slices.
Utility
Fundus Bumper Mechanical Reference for Easier Mechanism Deployment
23 Jun 22
Intrauterine devices and methods for facilitating deployment thereof using a bumper are disclosed.
Utility
Marking Device and Implantation System
23 Jun 22
Marking device (100) for implantation into a tissue (260), having a support structure (102) which is formed by at least one elastic metal wire, is compressible and is self-expanding and which, in an expanded state, encompasses an interior space (104), characterized in that the marking device (100) is designed to transform itself on its own from a compressed state into an expanded state, even against a tissue pressure prevailing at a tissue site to be marked, and the marking device (100) in the expanded state has a hollow, approximately spherical shape.
Utility
Systems and methods for pivoting compression paddles
21 Jun 22
The housing for a breast imaging system contains an x-ray source and is configured to rotate relative to the breast.
Utility
System and method for navigating x-ray guided breast biopsy
21 Jun 22
A method of performing a procedure on a breast of a patient includes compressing the breast of the patient with a paddle of an imaging system and performing an initial imaging procedure on the breast of the patient.